Diadema Partners LP Pro Qr Therapeutics N.V. Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
A detailed history of Diadema Partners LP transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Diadema Partners LP holds 158,023 shares of PRQR stock, worth $409,279. This represents 0.18% of its overall portfolio holdings.
Number of Shares
158,023Holding current value
$409,279% of portfolio
0.18%Shares
1 transactions
Others Institutions Holding PRQR
# of Institutions
82Shares Held
45.1MCall Options Held
31.4KPut Options Held
24.7K-
Adage Capital Partners Gp, L.L.C. Boston, MA9.6MShares$24.9 Million0.05% of portfolio
-
Privium Fund Management B.V.4.99MShares$12.9 Million3.12% of portfolio
-
Woodline Partners LP San Francisco, CA3.56MShares$9.21 Million0.07% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.83MShares$7.32 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY2.83MShares$7.32 Million1.38% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $185M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...